Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression [Corrigendum]
Kamijima K, Hashimoto S, Nagayoshi E, Koyama T. Neuropsychiatric Disease and Treatment. 2013;9:555–565. On page 559, right column, line 10 from the bottom: (0.9 to 1.2) should read (−0.9 to 1.2).Read the original article
Saved in:
Main Authors: | Kamijima K, Hashimoto S, Nagayoshi E, Koyama T |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/7ae11b17edee4be1baeacae0adfec8bd |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
by: Kamijima K, et al.
Published: (2013) -
Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
by: Kang RY, et al.
Published: (2015) -
Milnacipran: recent findings in depression
by: Guest editors: Stuart Montgomery (London, et al.
Published: (2010) -
Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
by: Jean-Pierre Olié, et al.
Published: (2010) -
Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
by: Aoki A, et al.
Published: (2014)